Replimune
Focus: Replimune is a clinical-stage oncolytic immunotherapy biotech focused on engineered viral therapies for solid tumors, with a pipeline spanning melanoma, gastric cancer, and multiple other oncology indications.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Open Jobs
0
4 recent layoff filings (12 mo) — 288 affected
- 4/17/2026 — Woburn, MA · 81 affected · Layoff
- 4/17/2026 — Woburn, MA · 81 affected · Layoff
- 4/13/2026 — Woburn, MA · 63 affected · Layoff
- +1 more
Source: state DOL filings via Big Local News
About Replimune
AI assessmentNot HiringNo open roles listed right now. Follow Replimune to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Observational study with no interventions
MelanomaClinical Trials (1)
NCT06887348A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
N/AHelp build intelligence for Replimune
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.